Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check6 days agoChange DetectedThe page's Study Documents section and several blocks listing study locations, investigators, and identifiers have been removed. This reduces visibility of critical trial materials and contact information, affecting the ability to review and engage with the study record.SummaryDifference19%

- Check14 days agoChange DetectedAdded help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) and header adjustments (Intervention/Treatment added; Intervention / Treatment removed) with Revision updated to v3.6.0, and the page now displays 'No longer looking for participants' to reflect closed enrollment.SummaryDifference0.4%

- Check21 days agoChange DetectedA new page revision tag Revision: v3.5.5 was added, replacing the previous tag Revision: v3.5.4. This indicates an updated version of the page content or its documentation.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page's Revision tag was updated from v3.5.3 to v3.5.4, signaling a newer version of the page has been published. This is a metadata-level update and does not specify which content was modified.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page’s release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This reflects a change in the ClinicalTrials.gov page revision, not the underlying study information.SummaryDifference0.0%

- Check70 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.